53857-60-6 Usage
Uses
Used in Pharmaceutical Industry:
2,4-DIBROMO-1-METHYL-1H-IMIDAZOLE is used as a reactant for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical properties make it a valuable component in the creation of diverse medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-DIBROMO-1-METHYL-1H-IMIDAZOLE is utilized as a building block in the production of fungicides and bactericides. Its incorporation into these products helps protect crops from various diseases and pests, ensuring a healthy and productive agricultural yield.
Used in Chemical Product Preparation:
2,4-DIBROMO-1-METHYL-1H-IMIDAZOLE also serves as a key component in the preparation of various chemical products. Its versatility and reactivity make it an essential ingredient in the synthesis of a wide range of organic compounds, further expanding its applications across different industries.
Safety Precautions:
Check Digit Verification of cas no
The CAS Registry Mumber 53857-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,8,5 and 7 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 53857-60:
(7*5)+(6*3)+(5*8)+(4*5)+(3*7)+(2*6)+(1*0)=146
146 % 10 = 6
So 53857-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H4Br2N2/c1-8-2-3(5)7-4(8)6/h2H,1H3
53857-60-6Relevant articles and documents
HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF
-
Paragraph 00639-00640, (2018/02/28)
Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.
QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS
-
Page/Page column 38; 39; 40, (2013/04/24)
This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pr
